Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases

Chellappan, DK; Sze Ning, QL; Su Min, SK; Bin, SY; Chern, PJ; Shi, TP; Ee Mei, SW; Yee, TH; Qi, OJ; Thangavelu, L; Rajeshkumar, S; Negi, P; Chellian, J; Wadhwa, R; Gupta, G; Collet, T; Hansbro, PM; Dua, K

Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases

Chellappan, DK Sze Ning, QL Su Min, SK Bin, SY Chern, PJ Shi, TP Ee Mei, SW Yee, TH Qi, OJ Thangavelu, L Rajeshkumar, S Negi, P Chellian, J Wadhwa, R Gupta, G Collet, T Hansbro, PM

Dua, K

Permalink

Publication Type:: Journal Article
Citation:: Chemico-Biological Interactions, 2019, 310
Issue Date:: 2019-09-01

Closed Access

	Filename	Description	Size
	Interactions between microbiome and lungs Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases.pdf	Published Version	2.08 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Chellappan, DK	en_US
dc.contributor.author	Sze Ning, QL	en_US
dc.contributor.author	Su Min, SK	en_US
dc.contributor.author	Bin, SY	en_US
dc.contributor.author	Chern, PJ	en_US
dc.contributor.author	Shi, TP	en_US
dc.contributor.author	Ee Mei, SW	en_US
dc.contributor.author	Yee, TH	en_US
dc.contributor.author	Qi, OJ	en_US
dc.contributor.author	Thangavelu, L	en_US
dc.contributor.author	Rajeshkumar, S	en_US
dc.contributor.author	Negi, P	en_US
dc.contributor.author	Chellian, J	en_US
dc.contributor.author	Wadhwa, R	en_US
dc.contributor.author	Gupta, G	en_US
dc.contributor.author	Collet, T	en_US
dc.contributor.author	Hansbro, PM https://orcid.org/0000-0002-4741-3035	en_US
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.date.available	2019-07-01	en_US
dc.date.issued	2019-09-01	en_US
dc.identifier.citation	Chemico-Biological Interactions, 2019, 310	en_US
dc.identifier.issn	0009-2797	en_US
dc.identifier.uri	http://hdl.handle.net/10453/135542
dc.description.abstract	© 2019 Elsevier B.V. Background: The human body is a home to thousands of microbiotas. It is defined as a community of symbiotic, commensal and pathogenic microorganisms that have existed in all exposed sites of the body, which have co-evolved with diet, lifestyle, genetic factors and immune factors. Human microbiotas have been studied for years on their effects with relation to health and diseases. Methods: Relevant published studies, literature and reports were searched from accessible electronic databases and related institutional databases. We used keywords, viz; microbiome, microbiota, microbiome drug delivery and respiratory disease. Selected articles were carefully read through, clustered, segregated into subtopics and reviewed. Findings: The traditional belief of sterile lungs was challenged by the emergence of culture-independent molecular techniques and the recently introduced invasive broncho-alveolar lavage (BAL) sampling method. The constitution of a lung microbiome mainly depends on three main ecological factors, which include; firstly, the immigration of microbes into airways, secondly, the removal of microbes from airways and lastly, the regional growth conditions. In healthy conditions, the microbial communities that co-exist in our lungs can build significant pulmonary immunity and could act as a barrier against diseases, whereas, in an adverse way, microbiomes may interact with other pathogenic bacteriomes and viromes, acting as a cofactor in inflammation and host immune responses, which may lead to the progression of a disease. Thus, the use of microbiota as a target, and as a drug delivery system in the possible modification of a disease state, has started to gain massive attention in recent years. Microbiota, owing to its unique characteristics, could serve as a potential drug delivery system, that could be bioengineered to suit the interest. The engineered microbiome-derived therapeutics can be delivered through BC, bacteriophage, bacteria-derived lipid vesicles and microbe-derived extracellular vesicles. This review highlights the relationships between microbiota and different types of respiratory diseases, the importance of microbiota towards human health and diseases, including the role of novel microbiome drug delivery systems in targeting various respiratory diseases.	en_US
dc.relation.ispartof	Chemico-Biological Interactions	en_US
dc.relation.isbasedon	10.1016/j.cbi.2019.108732	en_US
dc.subject.classification	Toxicology	en_US
dc.subject.mesh	Lung	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Lung Diseases	en_US
dc.subject.mesh	Chronic Disease	en_US
dc.subject.mesh	Drug Delivery Systems	en_US
dc.subject.mesh	Microbiota	en_US
dc.title	Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases	en_US
dc.type	Journal Article
utslib.citation.volume	310	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Students
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	310	en_US

Abstract:

© 2019 Elsevier B.V. Background: The human body is a home to thousands of microbiotas. It is defined as a community of symbiotic, commensal and pathogenic microorganisms that have existed in all exposed sites of the body, which have co-evolved with diet, lifestyle, genetic factors and immune factors. Human microbiotas have been studied for years on their effects with relation to health and diseases. Methods: Relevant published studies, literature and reports were searched from accessible electronic databases and related institutional databases. We used keywords, viz; microbiome, microbiota, microbiome drug delivery and respiratory disease. Selected articles were carefully read through, clustered, segregated into subtopics and reviewed. Findings: The traditional belief of sterile lungs was challenged by the emergence of culture-independent molecular techniques and the recently introduced invasive broncho-alveolar lavage (BAL) sampling method. The constitution of a lung microbiome mainly depends on three main ecological factors, which include; firstly, the immigration of microbes into airways, secondly, the removal of microbes from airways and lastly, the regional growth conditions. In healthy conditions, the microbial communities that co-exist in our lungs can build significant pulmonary immunity and could act as a barrier against diseases, whereas, in an adverse way, microbiomes may interact with other pathogenic bacteriomes and viromes, acting as a cofactor in inflammation and host immune responses, which may lead to the progression of a disease. Thus, the use of microbiota as a target, and as a drug delivery system in the possible modification of a disease state, has started to gain massive attention in recent years. Microbiota, owing to its unique characteristics, could serve as a potential drug delivery system, that could be bioengineered to suit the interest. The engineered microbiome-derived therapeutics can be delivered through BC, bacteriophage, bacteria-derived lipid vesicles and microbe-derived extracellular vesicles. This review highlights the relationships between microbiota and different types of respiratory diseases, the importance of microbiota towards human health and diseases, including the role of novel microbiome drug delivery systems in targeting various respiratory diseases.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/135542